What is Rasagiline?

Rasagiline (Rasagiline) is an irreversible monoamine oxidase-B inhibitor used to treat symptoms of early-stage Parkinson's disease (PD) or as an adjuvant treatment for advanced Parkinson's disease. The racemic form of this drug was invented by Aspro Nicholas in the early 1970s, which was subsequently identified as a potential treatment for Parkinson's disease, identifying the R-isomer as the active form of the drug.

Parkinson's disease is characterized by the death of dopamine-producing cells, an enzyme called monoamine oxidase (MAO) that breaks down the neurotransmitter. MAO comes in two forms, MAO-A and MAO-B. MAO-B can break down dopamine; however, recent evidence suggests that MAO-A may be mostly or entirely responsible for dopamine metabolism. Rasagiline prevents the breakdown of dopamine by irreversibly binding to MAO-B. Dopamine is therefore more readily available, compensating to some extent for the reduced amount produced in the brains of people with Parkinson's disease.

The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 1mg*100 tablets produced by an Indian pharmaceutical factory may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.